MBRX Moleculin Biotech, Inc.

P/E 0.0445
Forward P/E --
Price/Sales --
Beta 1.828
Div Yield --
Market Cap --

Company Analysis

Latest News

Moleculin Biotech's second quarter 2026 loss was $1.40 per share with cash runway into early 2027

Moleculin Biotech's second quarter 2026 loss was $1.40 per share with cash runway into early 2027

Moleculin Biotech reported a net loss of $7.6 million and no revenue for the second quarter of 2026, as the company remains focused on its clinical pipeline....

🟢 Moleculin Biotech is trading 11.55% up today after positive preliminary MIRACLE trial efficacy data

Moleculin Biotech is trading $0.64 (+11.55%) after reporting second-quarter results and positive preliminary MIRACLE trial efficacy data. - The first 45...

🟢 Moleculin Biotech is trading 5% up today after Q2 results and MIRACLE trial progress

Moleculin Biotech is trading 5.01% up at $0.60 after second-quarter 2026 results and MIRACLE progress. - Preliminary results from 45 patients showed complete...

🟢 Moleculin Biotech is trading 5.52% up today as broader equities rise

Moleculin Biotech is trading at $0.55 (+5.52%) as broader equities rise, supporting risk appetite. - The Nasdaq Composite is up 0.62%, while the S&P 500 is up...

🔴 Moleculin Biotech is trading 6.15% down in after-hours trading after a sharp regular-session gain

Moleculin Biotech is trading 6.15% down at $0.49 after closing at $0.52 on August 12, 2026, following a sharp regular-session gain and after-hours reversal. -...

🟢 Moleculin Biotech is trading 10.56% up today after July CPI matched expectations

Moleculin Biotech is trading at $0.49 (+10.56%) amid broader market strength after July CPI matched expectations, reducing immediate rate-hike concerns. - No...

🟢 Moleculin Biotech is trading 5.62% up today as Nasdaq Composite gains 0.66%

Moleculin Biotech is trading 5.62% up at $0.47 amid a stronger broader market, with the Nasdaq Composite up 0.66%. - No verified company-specific announcement...

🔴 Moleculin Biotech is trading 5.84% down in pre-market with no verified company-specific negative announcement identified

Moleculin Biotech is trading 5.84% down at $0.42 after no verified company-specific negative announcement was identified for August 12, 2026. - The weakness...

🔴 Moleculin Biotech is trading 6.7% down in after-hours trading with no verified company-specific negative announcement identified

Moleculin Biotech is trading 6.7% down at $0.42 after-hours, with no verified company-specific negative announcement identified. - It closed at $0.45 on...

🟢 Moleculin Biotech is trading 5.2% up today after Q2 earnings and strong interim MIRACLE data

- Moleculin Biotech is trading at $0.45, up +5.16% on August 11, 2026. - The company announced its Q2 2026 earnings today. - Investor enthusiasm continues...

🟢 Moleculin Biotech is trading 6.88% up in after-hours trading on positive interim MIRACLE leukemia data

Moleculin Biotech is trading 6.88% up at $0.46 after the August 10, 2026 regular session closed at $0.43, with the move appearing linked to lingering...

Moleculin's Leukemia Drug Shows Promise in Hard-to-Treat Patients, but Can a Sub-Penny Stock Survive Its Own Dilution?

Moleculin's Leukemia Drug Shows Promise in Hard-to-Treat Patients, but Can a Sub-Penny Stock Survive Its Own Dilution?

Shares shifted as Moleculin Biotech climbed 10% to $0.45 on lingering enthusiasm from July 31 interim data showing its experimental cancer drug working in...

🟢 Moleculin Biotech is trading 10% up today after 37% blinded composite complete remission data

Moleculin Biotech is trading 10% up now at $0.45 after positive blinded MIRACLE AML data continued attracting investor attention. - The company has not...

🟢 Moleculin Biotech is trading 5% up today amid positive blinded MIRACLE AML data

Moleculin Biotech is trading at $0.43, up +5.03% from the August 7, 2026 close of $0.41, amid positive blinded MIRACLE AML data. • No new company announcement...

Moleculin Biotech Inc Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026

Moleculin Biotech is expected to report a Q2 2026 loss of $1.55 per share on zero revenue, with the current stock price of $4.85 trading significantly below...

🔴 Moleculin Biotech is trading 5% down today after its $9.3 million public offering

Moleculin Biotech is trading at $0.37 (-5.13%) as its recent $9.3 million public offering continues to weigh on shares. - Completed on August 3, 2026, the...

🟢 Moleculin Biotech is trading 6% up today as XBI rises 2.09%

Moleculin Biotech is trading 6.41% up at $0.41, supported by a broader biotech rally, with XBI up 2.09% during regular trading. - The stock remains volatile...

🔴 Moleculin Biotech is trading 5.5% down today as selling pressure from $9.3M public offering continues

Moleculin Biotech is trading 5.5% down at $0.39 as the stock continues to absorb heavy selling pressure tied to its recently announced $9.3 million public...

🟢 Moleculin Biotech is trading 7.23% up today in a volatile bounce from deeply oversold levels

Moleculin Biotech is trading at $0.44 (+7.23%) as shares stage a recovery following a sharp multi-day collapse triggered by a $9.3 million public offering and...

🔴 Moleculin Biotech is trading 5.2% down today on dilution pressure from a $9.3M public offering

Moleculin Biotech is trading 5.2% down today at $0.41 following a sharply discounted $9.3 million public offering that triggered a major dilution-driven...